1. Introduction {#s0005}
===============

Antibiotics have been used in animal agriculture for growth promotion (sub-therapeutic doses), disease prevention (prophylactic doses) and for the treatment of infection for over 50 years ([@bb0390] **)**. Years of research and practical experience have shown that antibiotic use significantly improves animal performance and health status ([@bb0075]). However, the use and misuse of in-feed antibiotics have led to problems with drug residues in animal products and increased bacterial resistance ([@bb0175]). As a result, the sub-therapeutic use of antibiotics has been totally banned in European countries since January 2006 ([@bb0035]) and other countries are seriously considering a similar ban. Therefore, alternatives to antibiotics are urgently needed.

A wide range of products have been tested as potential alternatives to antibiotics including organic and inorganic acids ([@bb0185]), oligosaccharides ([@bb0110]), probiotics ([@bb0205], [@bb0375]), herbal extracts ([@bb0415]) and antibodies ([@bb0070]). Among these, oral immunotherapy (passive immunization) with antibodies is a highly attractive and effective alternative approach due to its high specificity. Oral administration with antibodies derived from mammalian serum and colostrum and even monoclonal antibodies have been used successfully ([@bb0210]). However, with this technique, it is prohibitively expensive to obtain the large amount of antibody required to prevent and treat disease**.**

Recently, chicken egg yolk immunoglobulin, referred to as immunoglobulin Y (IgY) has attracted considerable attention as a means to prevent and control disease as it possesses a large number of advantages compared with treatment with mammalian IgG including cost-effectiveness, convenience and high yield ([@bb0020]). Under natural conditions, the serum IgY of laying hens is deposited in large quantities in the egg yolk in order to protect the developing embryo from potential pathogens ([@bb0165]). Thus, it is possible to immunize the hen against specific foreign pathogens thereby allowing the production of IgY with activity against these specific disease conditions.

Oral administration of specific IgY antibody has been shown to be effective against a variety of intestinal pathogens such as bovine and human rotaviruses, enterotoxigenic *Escherichia coli* (ETEC), bovine coronavirus, *Salmonella* spp., *Edwardsiella tarda*, *Yersinia ruckeri*, *Staphylococcus* and *Pseudomonas* ([@bb0290]). This review presents an overview of the potential to use immunotherapy with specific IgY for the prevention and treatment of terrestrial and aquatic animal diseases and speculates on the future of IgY technology.

2. Characteristics of chicken immunoglobulin Y (IgY) {#s0010}
====================================================

2.1. Advantages of IgY {#s0015}
----------------------

The use of chickens for the production of polyclonal antibodies provides many advantages over production methods using mammals ([Table 1](#t0005){ref-type="table"} ). The most significant advantage is that the collection of antibodies is non-invasive. In contrast to conventional methods where animals are often sacrificed in order to collect a sufficient amount of blood to obtain antibodies, production of antibodies in laying hens requires only the collection of eggs, and the high and long-lasting titers produced in chickens reduce the need for frequent booster injections. Another advantage is that due to the phylogenetic distance between chickens and mammals, chickens often more successfully produce antibodies against highly conserved mammalian proteins than do other mammals and require much less antigen to induce an efficient immune response.Table 1Comparison of the characteristics of mammalian IgG and chicken IgY.ParameterMammalian IgGChicken IgYAntibody samplingInvasiveNon-invasiveSource of antibodyBlood serumEgg yolkAntibody amount200 mg IgG/bleed (40 ml blood)50--100 mg IgY/egg (300 eggs/year)Frequency of collectionEvery two weeksEvery dayAmount of antibody/year5200 mg22,500 mgAmount of specific antibody\~ 5%2--10%Protein--A/G bindingYesNoInterference with mammalian IgGYesNoInterference with rheumatoid factorYesNoActivation of mammalian complementYesNoAdapted from [@bb0345].

A hen can be considered as a small "factory" for antibody production. A hen usually lays about 300 eggs per year and the egg yolk (15 ml) contains 50--100 mg of IgY of which 2 to 10% are specific antibodies ([@bb0340]). Therefore, one immunized hen produces more than 22,500 mg of IgY per year which is equivalent to the production of 4.3 rabbits over the course of a year ([@bb0345]). The maintenance costs for keeping hens are also lower than those for mammals such as rabbits ([@bb0345]). Therefore, egg yolk provides a more hygienic, cost-efficient, convenient and rich source of antibodies compared with the traditional method of obtaining antibodies from mammalian serum. In contrast to antibiotics, the use of IgY is environmentally-friendly and elicits no undesirable side effects, disease resistance or toxic residues ([@bb0065]).

2.2. Structure and function of chicken IgY {#s0020}
------------------------------------------

Initially, IgY antibodies were thought to be similar to IgG immunoglobulins, whereas they are now considered to be an evolutionary ancestor to mammalian IgG and IgE and also to IgA ([@bb0400]). Although chicken IgY is the functional equivalent of mammalian IgG, there are some profound differences in their structure. The general structure of the IgY molecule is the same as the IgG molecule with two heavy (H) chains and two light (L) chains but IgY has a molecular mass of 180 kDa which is larger than that of mammalian IgG (150 kDa) ([Fig. 1](#f0005){ref-type="fig"} ). The molecular mass (67--70 kDa) of the H chain in IgY is larger than the H chain from mammals (50 kDa). The greater molecular mass of IgY is due to an increased number of heavy-chain constant domains and carbohydrate chains ([@bb0400]). IgG has 3 C regions (C~γ~1--C~γ~3), while IgY has 4 C regions (C~υ~1--C~υ~4) and the presence of one additional C region with its two corresponding carbohydrate chains logically results in a greater molecular mass of IgY compared with IgG.Fig. 1Structure of IgG and IgY.From [@bb0305].

Other differences in structure include the fact that the hinged region of IgY is much less flexible compared with mammalian IgG. It has also been suggested that IgY is a more hydrophobic molecule than IgG ([@bb0080]). Finally, IgY has an isoelectric point of pH 5.7--7.6, whereas that of IgG lies between 6.1 and 8.5 ([@bb0080], [@bb0370]).

Unlike mammalian IgG, IgY does not fix mammalian complement and does not interact with mammalian Fc and complement receptors ([@bb0020]). As well, IgY does not bind to protein A, protein G or rheumatoid factor, so no false positives are obtained on immunoassay which is a problem with IgG-based mammalian assays ([@bb0080]). These differences provide significant advantages to the application of IgY technology in many areas of research such as diagnostics ([@bb0105]), antibiotic-alternative therapy ([@bb0020]) and xenotransplantation ([@bb0115]).

2.3. Storage stability of IgY {#s0025}
-----------------------------

The stability of IgY during storage is reasonably good under specified conditions. IgY solutions may be stored at 4 °C for periods ranging from months to a few years provided 0.02% NaN~3~, 0.03% w/v thimerosal or 50 μg/ml gentamicin has been added to retard microbial growth ([@bb0345]). Dried IgY preparations were stored for five to ten years at 4 °C without significant loss of antibody activity and the preparations also retained activity for six months at room temperature and for one month at 37 °C ([@bb0230]). While lyophilization minimizes bacterial growth and maintains better structural integrity of purified IgY, spray-drying is more economical ([@bb0435]). Collectively, these unique biological attributes make IgY an effective natural food antimicrobial system and immunotherapeutic agent.

3. Mode of action {#s0030}
=================

The exact mechanisms through which IgY counteracts pathogen activity have not been determined. However, several mechanisms have been proposed to express how specific IgY counteracts pathogen activity and these are outlined below.

(i)*Agglutination*. [@bb0385] suggested that the inhibition of bacterial growth or colonization observed as a result of treatment with IgY can be the result of bacterial agglutination, causing a reduction in CFU rather than actual direct effects on individual bacteria. Although agglutination may be one mediator of growth inhibition, it is unlikely to be the most important mediator because cross-linking of bacteria is precluded by the steric hindrance of the two Fab arms of IgY ([@bb0125]).(ii)*Adherence-blockade*. Several in vitro studies have suggested that inhibition of adhesion is the dominant mechanism by which specific IgY counteracts pathogen activity ([@bb0170], [@bb0245]). [@bb0170] showed that IgY functions to prevent the adherence of *E. coli* K88 to the intestinal mucus of piglets. Particular components exposed on the Gram-negative bacteria surface such as outer membrane protein, lipopolysaccharide, fimbriae (or pili), and flagella, which are crucial factors for bacterial colonization, may be recognized and bound by related polyclonal antibody such as IgY ([@bb0355]). This binding may block or impair the functions of growth-related bacterial components and lead to bacterial growth inhibition. It is also possible that specific IgY binding to bacteria could alter cellular signaling cascades that could result in decreased toxin production and release.(iii)*Opsonization followed by phagocytosis*. [@bb0475] determined that IgY improved the phagocytosis of *S. aureus* by neutrophils. Similarly, [@bb0465] showed that phagocytic activity of *E. coli* by either milk macrophages or by polymorphonuclear neutrophil leukocytes increased significantly in the presence of IgY. These results suggest that IgY enhanced phagocytic activity. Structural alterations were observed on the surface of *S. typhimurium* ([@bb0245]) and *E. coli* O111 ([@bb0465]) by binding with specific IgY. These changes could be explained by the variation of the electron cloud and/or electric field on the bacterial surface ([@bb0245]), resulting in greater vulnerability of the bacterial cells to phagocytosis.(iv)*Toxin neutralization*. *S. aureu*s capsular is a major virulence factor involved in the onset of bovine mastitis. Wang et al. (2011) studied the effectiveness of IgY against encapsulated *S. aureus*. Their results showed that IgY could prevent *S. aureus* internalization by mammary epithelial cells suggesting toxin neutralization activity, rather than direct growth inhibition as the means through which IgY acts to control mastitis.

4. Applications for IgY administration {#s0035}
======================================

The potential applications for using orally administered IgY in the control of enteric and non-enteric infections of either bacterial or viral origin in humans and animals have been studied at length and are summarized in [Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"} .Table 2Investigations on the use of specific IgY for the control of enteric diseases.PathogensEffects of IgYRef.RotavirusProtecting calves from bovine rotavirus-induced diarrhea[@bb0215]Preventing murine rotavirus in mice[@bb0450]Preventing human rotavirus-induced gastroenteritis in mice[@bb0095]Prevention and treatment of rotavirus-induced gastroenteritis in murine model[@bb0145]Prevention of rotavirus infection in vitro, using IgY against recombinant HRV coat protein, VP8\*[@bb0195]CoronavirusProtecting neonatal calves from bovine coronavirus (BCV)-induced diarrhea[@bb0160]*Escherichia coli*Preventing K88+, K99+, 987P + ETEC infection in neonatal piglets[@bb0435]Protecting neonatal calves from fatal enteric colibacillosis by K99-pilated ETEC[@bb0155]Inhibiting adhesion of ETEC K88 to piglet intestinal mucus[@bb0170]Prevention of ETEC K88+ infection in neonatal and early weaned piglets[@bb0280]*Salmonella*Protecting mice challenged with *S. enteritidis* or *S. typhimurium* from salmonellosis[@bb0445]Preventing fatal salmonellosis in neonatal calves exposed to *S. typhimurium* or *S. dublin*[@bb0445]Inhibiting adhesion of *S. enteritidis* to human intestinal cells[@bb0365]*Yersinia*Protection of rainbow trout against *Y. ruckeri* infection[@bb0240]*Edwardsiella*Preventing Edwardsiellosis of Japanese eels infected with *Edwardsiella tarda*[@bb0360]IBDVProtecting chicks from infectious bursal disease virus[@bb0135]*Staphylococcus*Inhibiting the production of *S. aureus* enterotoxin-A[@bb0365]*Pseudomonas*Inhibiting the growth of *P. aeruginosa*[@bb0365]From [@bb0290].Table 3Investigations on the use of specific IgY in the control of non-enteric diseases.PathogensEffects of IgYRef.*Streptococcus mutans*Protecting rats from *S. mutans*-induced dental caries[@bb0140]Snake venomsNeutralizing the toxic and lethal components of the venoms[@bb0285]SARS coronavirusPrevention of SARS-coronavirus infection in vitro[@bb0120]Avian influenza virusProtecting birds from avian influenza Subtype H9N2[@bb0320]

4.1. Application of IgY in the control of livestock diseases {#s0040}
------------------------------------------------------------

### 4.1.1. Bovine mastitis {#s0045}

Bovine mastitis is a costly disease for the dairy industry. In the United States alone, the annual costs of mastitis have been estimated to be \$1.5--2.0 billion (\$US). Numerous pathogens can cause mastitis and these can be classified into contagious pathogens (primary *Staphylococcus aureus* and *Streptococcus agalactiae*) or environmental pathogens (primary *E. coli;* [@bb0335]).

In our research, we have reported that specific IgY produced by hens immunized with *S. aureus* and/or *E. coli* was effective in controlling experimental and clinical mastitis ([@bb0460], [@bb0465], [@bb0470]). An in vitro study conducted in our laboratory indicated that IgY could inhibit the growth of bacteria by altering the bacterial cell surface thereby reducing the ability of bacteria to adhere to mammary epithelial cells ([@bb0465]). In a further study, the efficacy of specific IgY to reduce clinical and experimental mastitis caused by *S. aureus* was demonstrated by improving milk quality through a decrease in somatic cell and bacterial counts in milk ([@bb0470]). The cure rates resulting from the use of IgY for clinical and experimental mastitis were dramatically higher than for untreated animals ([Table 4](#t0020){ref-type="table"} ). Although conducted with very few animals, these studies indicate that specific IgY has considerable potential as a therapeutic treatment for mastitis in dairy cows.Table 4Comparison of IgY and penicillin for the treatment of experimental and clinical mastitis caused by *S. aureus*[a](#tf0010){ref-type="table-fn"}.TreatmentExperimental mastitis[b](#tf0015){ref-type="table-fn"}Clinical mastitis[c](#tf0020){ref-type="table-fn"}No. of mastitic quartersNo. of cured quartersNo. of mastitic quartersNo. of cured quartersIgY65 (83.3%)[⁎](#tf0005){ref-type="table-fn"}63 (50.0%)[⁎](#tf0005){ref-type="table-fn"}Penicillin64 (66.7%)[⁎](#tf0005){ref-type="table-fn"}62 (33.3%)[⁎](#tf0005){ref-type="table-fn"}No treatment6060[^1][^2][^3][^4]From [@bb0470].

### 4.1.2. Diarrhea in piglets {#s0050}

Enterotoxigenic *E. coli* (ETEC) is by far the most common cause of enteric colibacillosis encountered in neonatal and post-weaned pigs ([@bb0435]). The strains of *E. coli* associated with intestinal colonization which cause severe diarrhea are the K88, K99 and 987P fimbrial adhesins. Among the ETEC, those expressing the K88+ fimbrial antigen are the most prevalent forms causing *E. coli* infection world-wide ([@bb0330]). It has been estimated that K88+ ETEC are responsible for more than half of the piglet mortality which occurs each year ([@bb0405]), causing significant economic loss for the pig industry.

IgY is recognized as an alternative source of antibodies for the prevention of ETEC coli infection because it has been found to inhibit binding of *E. coli* to the intestinal mucosa ([@bb0170]). IgY has been orally administered to piglets and offers a potential prophylactic and therapeutic approach for controlling *E. coli*-induced diarrhea. [@bb0435] showed that orally administered IgY generated against *E. coli* K88, K99, or 987P fimbriae was protective against infection from each of the three homologous strains of *E. coli* in a dose-dependent manner. *E. coli* K88, K99, and 987P strains adhered equally to porcine epithelial cells from the duodenum and ileum but failed to so in the presence of homologous anti-fimbrial IgY.

A group of researchers at the University of Manitoba (Winnipeg, Canada) have carried out some excellent studies on the passive protective effect of IgY against ETEC K88 fimbriae in the control of neonatal and early-weaned piglets in vitro and in vivo ([@bb0170], [@bb0280]). In an animal feeding study, 21-day old pigs were challenged with 5 ml of ETEC K88 at a dose of 10^12^  CFU ml^− 1^ per piglet. IgY was administered to piglets three times a day for two days. Control piglets (treated with IgY from non-immunized hens) developed severe diarrhea within 12 h and 30% of the pigs died. In contrast, the pigs given IgY from immunized hens exhibited no signs of diarrhea when observed 24 and 48 h after treatment ([Table 5](#t0025){ref-type="table"} ). Furthermore, the field study showed the suppression of the incidence and severity of diarrhea in 14--18-day-old weaned piglets fed specific IgY powder, which was much lower than in those fed a commercial diet containing an antibiotic. The number of pigs in this study was not large and it would be desirable to repeat this study with a greater number of animals.Table 5Clinical response of 21-day-old pigs after challenge with ETEC K88+ MB and treatment with egg-yolk antibodies.Treatment[a](#tf0025){ref-type="table-fn"}No. of pigsNo. of pigs with diarrhea (FC score[b](#tf0030){ref-type="table-fn"}) afterWeight gain (g)% of pigs dead24 h48 h72 h*E. coli* challenged103/108/104/7− 36.230.0%(1.0)(2.0)(3.0)*E. coli* challenged + IgY105/100/101/10+ 90.60.0%(1.6)(0.0)(0.5)[^5][^6]From [@bb0280].

ETEC can cause severe diarrhea in young animals by proliferation in the small intestine and through the production of two types of enterotoxins including a heat-labile enterotoxin (LT) and a family of heat-stable enterotoxins (ST) that includes STa and STb ([@bb0090]). These enterotoxins are crucial virulence factors and therefore effective programs for immunological protection against ETEC-mediated diarrhea should include antitoxic immunity ([@bb0025]). Because of their small size, enterotoxins STa and STb are poorly immunogenic, but they can attain immunogenicity when coupled chemically or genetically to an appropriate carrier ([@bb0060], [@bb0085]).

Antitoxinic antibodies were shown to be important in the prevention of *E. coli*-induced diarrhea. Considering the limited number of classes of enterotoxins, enterotoxin-based vaccines should provide broad-spectrum protection against various ETEC. In order to make the useful toxoids, polyvalent enterotoxin STa--LTB--STb DNA and protein vaccines endowing immunogenicity to both STa and STb were constructed ([@bb0455]). We immunized laying hens with DNA vaccines and obtained antitoxic antibodies from egg yolks and this was confirmed by indirect ELISA. The polyvalent DNA vaccine pCI--STa--LTB--STb expressed the STa--LTB--STb fusion peptide in vitro in cultured Hela cells. These egg yolk antibodies were able to neutralize the biological activity of ST and LT ([@bb0490]). Therefore, the trivalent fusion enterotoxin STa--LTB--STb has the potential to serve as a useful toxin-based vaccine which can provide broad protection against ETEC-induced diarrhea.

### 4.1.3. Diarrhea in calves {#s0055}

Neonatal calf diarrhea caused by bovine rotavirus (BRV) is a common disease and causes high mortality in cattle ([@bb0235]). Anti-BRV IgY has been shown to successfully provide protection against BRV infection in calves ([@bb0215]).

Bovine corona virus (BCV) is an important enteric pathogen that is responsible for both neonatal calf diarrhea and acute diarrhea in adult cattle. BCV may be more severe than BRV as it replicates in the epithelium of both the small and large intestine whereas BRV infects only the small intestine. [@bb0160] examined the efficacy of specific IgY antibodies and cow colostrum antibodies to BCV-induced diarrhea in calves. They found that control calves which received no antibodies developed severe diarrhea resulting in all calves dying within 6 days of BCV challenge whereas calves treated with milk containing egg yolk or colostrum had positive weight gains and none of these calves died ([Table 6](#t0030){ref-type="table"} ). This study was conducted with very few animals and a larger study should be conducted to confirm these findings. However, these results do indicate that orally administered egg yolk or colostral antibodies have the potential to passively protect calves against BCV infection and the effect of IgY was higher than that of colostrum alone indicating that the passive immunization strategy with IgY provided a more efficacious alternative to existing treatments for BCV. The passive protective effects of using anti-ETEC IgY administration on fatal enteric colibacillosis in neonatal calves have also been studied ([@bb0155]). Calves fed milk containing IgY had only transient diarrhea, 100% survival and exhibited good body weight gains during the course of the study. In contrast, the controls which received no antibody had severe diarrhea and all died within 6 days of infection.Table 6Clinical response of calves to challenge exposure with bovine coronavirus and subsequent treatment with egg yolk powder.GroupAntibody titerNo. diarrhea/total no. (%)No. dead/total no. (%)Cumulative fecal scoreWeight gain (%)Control--4/4 (100)4/4 (100)30.5 ± 6.1− 7.4 ± 2.3Egg powder12803/4 (75)2/4 (50)20.0 ± 7.4− 5.1 ± 10.4Egg powder25603/4 (50)0/4 (0)[⁎](#tf0035){ref-type="table-fn"}3.8 ± 3.8[⁎⁎](#tf0040){ref-type="table-fn"}6.3 ± 2.4[⁎⁎](#tf0040){ref-type="table-fn"}[^7][^8]From [@bb0160].

4.2. Applications of IgY in the control of poultry diseases {#s0060}
-----------------------------------------------------------

### 4.2.1. Salmonellosis {#s0065}

*Salmonella* infections are thought to be responsible for a variety of acute and chronic diseases of poultry. It has been shown that specific IgY against *Salmonella enteritidis* or *Salmonella typhimurium* inhibits bacterial growth in vitro ([@bb0245]). Studies have demonstrated that egg derived anti-*S. entritidis* IgY antibody had a beneficial effect in reducing the colonization of *Salmonella* in market-aged broilers ([@bb0325], [@bb0380]) ([Table 7](#t0035){ref-type="table"} ). Whether or not this translates into improvements in broiler performance has not been determined.Table 7Effect of specific IgY on the concentration of *Salmonella* in the cecum of broiler chickens.Age of birdLog~10~*Salmonella* per gram cecal contentsControlIgYDay 215.26^b^1.23^a^Day 283.98^b^0.27^a^[^9]From [@bb0325].

The use of whole egg powder (containing antibody) as a feed additive may be an alternative way to reduce the rate of *Salmonella* contamination of eggs. [@bb0130] found that in the experimental group, 13.3% of the eggs were *Salmonella* positive, which was significantly lower than the 29.4% *Salmonella-*positive eggs in the control group (*p*  ≤ 0.001) ([Table 8](#t0040){ref-type="table"} ). However, it must be pointed out that the majority of the *Salmonella* was found on the shell and there were only modest differences in *Salmonella* numbers in the albumen and yolk. Whether or not this translates into any less health risk for consumers of egg products is not known at this time.Table 8Rate of *Salmonella* isolation in eggs laid by hens after oral application of IgY egg powder.Parts% Eggs with *Salmonella*IgYControlp valueWhole eggs13.329.4*p* ≤ 0.001Egg shell13.329.2*p* ≤ 0.001Albumen0.30.5n.s.Yolk0.62.4*p* ≤ 0.05From [@bb0130].

### 4.2.2. *Campylobacteriosis* {#s0070}

*Campylobacter jejuni* has become a major concern to the commercial broiler, turkey and commercial egg-producing flocks in all countries. [@bb0385] used egg yolk antibodies for prophylactic and therapeutic applications in *Campylobacter*-infected chickens. In a prophylaxis experiment, it was found that these antibodies caused a 99% decrease in the number of *Campylobacter* observed, whereas in a therapy trial (antibodies were given after establishment of the infection), the number of bacteria in the feces was 80--95% lower. Unfortunately, bird performance was not monitored in this study.

### 4.2.3. Infectious bursal disease {#s0075}

Infectious bursal disease (IBD) is an acute, highly contagious disease of young chickens caused by IBD virus ([@bb0050]). Early sub-clinical infections which usually result in immunosuppression are the most important form of this disease because of the large economic loss that results from their presence. Chickens immunosuppressed by early IBD infections do not respond well to vaccination and show increased susceptibility to other diseases such as bacterial infection with *E. coli* or viral infections like bronchitis or inclusion body hepatitis ([@bb0295]). Antibiotic therapy is the most readily-available approach for controlling IBD-induced secondary bacterial infections in affected flocks. It has been shown that specific IgY has a great potential as an alternative to antibiotics for IBD. [@bb0300] demonstrated that yolks from hyper-immunized hens can be used to control IBD in commercial laying hens. The IBD infected broilers (28 days old) treated with the yolk induced 80% recovery while all the control (untreated) birds died.

### 4.2.4. Newcastle disease {#s0080}

Newcastle disease is a severe viral infection causing a respiratory nervous disorder in several species of poultry including chickens and turkeys. This disease is endemic in commercial poultry from many countries and can cause great economic loss due to high mortality rates ([@bb0225]). Vaccination has been used to prevent this disease in endemic areas, but vaccines are not always effective and vaccinated flocks may still be infected. When outbreaks of Newcastle disease occur in a commercial poultry flock, antibiotics may be given to prevent secondary bacterial infections which are usually triggered by this disease. It has been shown that egg yolk antibodies conferred protection in chickens against Newcastle disease ([@bb0015], [@bb0410]). [@bb0410] have found that subcutaneous administration of egg yolk containing high levels of IgY antibody specific to Newcastle disease protected 80% of the birds during a four-week study period.

4.3. Applications of IgY in the control of aquatic diseases {#s0085}
-----------------------------------------------------------

### 4.3.1. Shrimp white spot syndrome virus {#s0090}

White spot syndrome virus (WSSV) is a virulent pathogen causing high mortality and significant economic loss in cultured shrimp operations worldwide ([@bb0425]). As with other invertebrates, shrimp lack a true adaptive immune response system ([@bb0190]). However, shrimp may exhibit a quasi-immune response which possibly shows WSSV-specific effects ([@bb0420], [@bb0430]). WSSV can be neutralized by chicken IgY produced against a truncated fusion protein of VP28 and VP19 ([@bb0180]) and therefore, passive immunization with IgY against WSSV has potential for immunotherapeutic application to prevent WSSV infection in shrimp.

Some researchers have demonstrated passive immunization by anti-viral egg yolk antibodies (IgY) ([@bb0005], [@bb0220]). However, our research work ([@bb0270]) represents the first report of the passive immunization of shrimp with IgY obtained from the egg yolk of chickens vaccinated with a DNA vaccine comprising genes encoding structural proteins of WSSV or with inactivated WSSV. Our work showed that IgY antibodies have a high affinity for WSSV and maintained good biological and neutralization activity especially when induced by the traditional inactivated vaccine. IgY antibody induced by the DNA vaccine was also able to neutralize disease in shrimp experimentally challenged with WSSV but was still inferior to inactivated WSSV ([@bb0270]). Using specific IgY from hens immunized with inactivated WSSV and DNA vaccine to neutralize WSSV, the challenged shrimp had 73.3 and 33.3% survival, respectively ([Fig. 2](#f0010){ref-type="fig"} ). As well, the effectiveness of IgY provided by intramuscular injection, oral administration, and immersion was investigated in crayfish (*Procambius clarkiaii*) challenged with WSSV ([@bb0275]). Our results showed that immunization of specific IgY antibodies through intramuscular injection, oral administration or immersion were all effective means of protecting crayfish against WSSV. Unfortunately, these are labor intensive techniques and may have limited application under commercial aquaculture conditions where crayfish are raised in the ocean.Fig. 2Effect of IgY on the survival rate of shrimp challenged with white spot syndrome virus.From [@bb0270].

Egg yolk antibodies can be harvested in a more cost efficient and convenient manner compared with production of antibody from mammals ([@bb0290]). IgY in egg yolk could be prepared in different forms such as egg yolk powder, purified powder and liquor which may provide a feasible and significant way forward in research using antibodies against WSSV.

### 4.3.2. *Y. ruckeri* {#s0095}

The effectiveness of IgY in passive immunization of rainbow trout against *Y. ruckeri* infection has been studied ([@bb0240]). *Y. ruckeri* is the aetiological agent of enteric red mouth disease, a systemic bacterial septicaemia, principally affecting farmed rainbow trout, *Oncorhynchus mykiss* ([@bb0360]). *Y. ruckeri* could persist for long periods in carrier fish and are shed in feces, representing a continuing source of infection. If a population of asymptomatic carrier fish could be adequately cleared by oral administration of anti-*Y. ruckeri* antibody, such treatment might be a cost-effective alternative approach to the slaughter of a stock of fish with a potential health risk. Rainbow trout fed with anti-*Y. ruckeri* IgY, 2 h before an immersion challenge with *Y. ruckeri,* showed a lower mortality rate after 8 days than did fish fed unsupplemented IgY feed before the challenge ([@bb0240]). The fish fed IgY also appeared to have fewer infections after 8 days, based on organ and intestinal cultures. In a subsequent trial, the IgY-fed fish had lower mortality than fish receiving unsupplemented IgY feed ([@bb0240]). The percentage of IgY-fed fish carrying *Y. ruckeri* in their intestinal samples appeared to be lower than in the untreated controls, regardless of whether the IgY containing feed was given before or after the challenge. The oral administration of specific IgY against fish pathogens could provide an alternative method to antibiotics and chemotherapy for prevention of bacterial diseases of fish in fish farm.

### 4.3.3. *E. tarda* {#s0100}

*E. tarda* is another important fish pathogen which is spread by infection through the intestinal mucosa ([@bb0310]). Edwardsiellosis in Japanese eels has become a serious problem for the eel farming industry ([@bb0395]). Egg yolk antibodies have been investigated for the prevention of this infectious disease because the use and misuse of antibiotics has led to growing problems with drug residues in fish products and increased bacterial resistance ([@bb0135], [@bb0150]). Anti-*E. tarda* IgY were simultaneously administered orally to Japanese eels (*Anguilla japonica*) with the pathogenic bacteria (10^5^--10^6^  CFU per fish). The non-treated infected eels died within 15 days whereas the eels receiving IgY survived and no disease symptoms were observed, suggesting that anti-*E. tarda* IgY is effective in preventing edwardsiellosis ([@bb0135]). Again limited numbers of eels were used in this study and a repeat with greater numbers would certainly be welcomed.

5. Limitations of IgY technology {#s0105}
================================

There are limitations to the use of IgY for oral passive immunotherapy due to its susceptibility to proteolysis. IgY is fairly resistant to digestion by intestinal proteases ([@bb0145], [@bb0350]). However, it was found that the activity of IgY was decreased at pH 3.5 and completely lost at pH 3.0 ([@bb0350]). IgY has a serum half-life of 1.85 days in newborn pigs. This is shorter than the reported serum half-life of 12 to 14 days for homologous IgG (colostral antibodies). The fraction of IgY absorbed into the circulation when administered in pigs decreased with increasing age of pigs ([@bb0440]).

Since the primary target site of IgY is the small intestine, in order for it to function it is essential to find an effective method to protect IgY against peptic digestion and acidity in the stomach. It has been shown that microencapsulation can be an effective method for protecting IgY from gastric inactivation ([@bb0045], [@bb0055], [@bb0200], [@bb0255], [@bb0260]), but this process will undoubtedly add additional costs. Additional study will be needed before microencapsulation can be applied under commercial conditions.

In vitro studies have demonstrated that IgY is effective against many Gram-negative bacteria. In contrast, inhibition activity of IgY on Gram-positive bacteria has only occasionally been reported ([@bb0365], [@bb0460], [@bb0470], [@bb0480]). This may be due to the fact that Gram-positive bacteria have a more compact cell wall compared with Gram-negative bacteria. However, this clearly limits the types of diseases that can be treated with IgY technology.

The objective to treatment with IgY is not always prevention of a disease but sometimes simply a reduction of infectious agents ([@bb0315]). Unlike mammalian IgG, IgY does not bind complement or acts as an opsonin in phagocytosis. Therefore, IgY are unable to kill bacteria directly. It was also shown that IgY antibodies were not able to displace *E. coli* K88+ MB once bound to the mucosal receptor. This indicates that the antibodies have a lower affinity for the receptor than that of K88+ fimbriae. Since IgY could not remove previously bound *E. coli* K88+ MB from the mucus, a prophylactic use for IgY is suggested ([@bb0170]). However, therapeutic effects of IgY in the control of infections have been reported, such as *E. coli* K88 in piglets ([@bb0435], [@bb0485]), *C. jejuni* in chickens ([@bb0385]) and *Salmonella* in mice ([@bb0445]).

At present, the production cost of high quality IgY antibodies is higher than the cost of routine antibiotics ([@bb0030]). Therefore, the development of methods for large-scale production of IgY with high recovery and purity are needed. The method should be simple, economical and requires few chemicals. In addition, there is no consensus on the most suitable IgY extraction method for commercial application ([@bb0345]) and this requires further study.

6. Conclusions {#s0110}
==============

Oral administration of chicken egg yolk immunoglobulin appears to have considerable potential as a means of controlling infectious diseases of bacterial and viral origin and may be the disease treatment of the future. To date, IgY technology has been used for the treatment of livestock diseases such as mastitis and diarrhea, poultry diseases such as *Salmonella*, *Campylobacteriosis,* infectious bursal disease and Newcastle disease, as well as aquatic diseases like shrimp white spot syndrome virus, *Y. ruckeri* and *E. tarda*. Some advantages of IgY in the control of animal diseases are:1.They are highly effective.2.They are cost effective.3.Collection of eggs is non-invasive.4.The treatment is safe and live organisms are not used.5.The procedure is environmentally friendly.6.No toxic residues are produced and there is no development of resistance.7.The treatment can be used to control many different types of pathogens.
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[^1]: *p* \< 0.05 compared with no treatment in the same group.

[^2]: Ten milliliters of IgY, at a concentration of 20 mg ml^− 1^, or penicillin, at a concentration of 100 mg ml^− 1^, were infused into the mammary glands immediately after the cow\'s morning and evening milking for six consecutive days.

[^3]: Mammary glands selected for clinical mastitis treatment met the following criteria: obvious clinical signs of mastitis were detected, *S. aureus* counts of the milk samples were 100--200 CFU ml^− 1^, somatic cell counts were more than 5 × 10^5^ cells ml^− 1^.

[^4]: Mammary glands selected for inducing experimental mastitis met the following criteria: no clinical signs of mastitis were detected, *S. aureus* counts of the milk were less than 10 CFU ml^− 1^ and no other bacteria were detected, somatic cell counts were less than 1 × 10^5^ CFU ml^− 1^. Experimental mastitis was induced by mammary infusion with 10^7^ CFU ml^− 1^ of *S. aureus*.

[^5]: All the 21-day-old piglets were challenged orally two times (at 0 and 5 h) with a dose of 10^12^ CFU ml^− 1^ of viable organism per piglet. Piglets in the *E. coli* challenged + IgY group were treated with 0.5 g of egg yolk antibodies, three times a day (− 1, 4 and 9 h after the first ETEC challenge) for the first day and once a day for the next two days after the first ETEC challenge.

[^6]: FC score is the mean fecal consistency score: 0, normal; 1, soft feces; 2, mild diarrhea; 3, severe diarrhea. Pigs with a fecal score of ≤ 1 were considered not to have diarrhea.

[^7]: *p* \< 0.05.

[^8]: *p* \< 0.01.

[^9]: ^a,b^ Means in the same row lacking a common superscript differ significantly (*p* \< 0.01).
